AVDL - Avadel Pharmaceuticals PLC Stock Price, Fair Value and News

16.73USD+0.44 (+2.70%)Market Closed

Market Summary

USD16.73+0.44

Market Closed

2.70%

AVDL Stock Price

View Fullscreen

AVDL RSI Chart

AVDL Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-10.25

Price/Sales (Trailing)

29.21

EV/EBITDA

-10.35

Price/Free Cashflow

-12.56

AVDL Price/Sales (Trailing)

AVDL Profitability

EBT Margin

-284.61%

Return on Equity

-200.08%

Return on Assets

-93.41%

Free Cashflow Yield

-7.96%

AVDL Fundamentals

AVDL Revenue

Revenue (TTM)

55.0M

Rev. Growth (Yr)

14.0K%

Rev. Growth (Qtr)

40.41%

AVDL Earnings

Earnings (TTM)

-156.8M

Earnings Growth (Yr)

11.18%

Earnings Growth (Qtr)

5.02%

Breaking Down AVDL Revenue

Last 7 days

3.3%

Last 30 days

16.7%

Last 90 days

-6.1%

Trailing 12 Months

21.8%

How does AVDL drawdown profile look like?

AVDL Financial Health

Current Ratio

2.85

AVDL Investor Care

Shares Dilution (1Y)

25.21%

Diluted EPS (TTM)

-1.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	55.0M	0	0	0
2023	1.6M	2.3M	9.2M	28.1M
2022	0	1.9M	1.9M	0
2021	17.3M	12.3M	7.3M	2.3M
2020	55.0M	47.6M	33.3M	22.3M
2019	86.4M	74.7M	69.1M	59.2M
2018	154.4M	136.6M	116.7M	103.3M
2017	166.2M	175.1M	182.7M	173.6M
2016	176.6M	166.2M	150.9M	149.9M
2015	54.5M	94.0M	133.6M	173.1M
2014	6.9M	9.6M	12.3M	15.0M
2013	6.7M	5.9M	5.0M	4.2M
2012	26.3M	20.1M	13.8M	7.5M
2011	35.6M	34.1M	0	32.6M
2010	0	0	0	37.1M
2009	0	0	0	42.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

CEO	Mr. Gregory J. Divis Jr.
WEBSITE	avadel.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	41

Avadel Pharmaceuticals PLC Frequently Asked Questions

What is the ticker symbol for Avadel Pharmaceuticals PLC? What does AVDL stand for in stocks?

AVDL is the stock ticker symbol of Avadel Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avadel Pharmaceuticals PLC (AVDL)?

As of Fri Jul 26 2024, market cap of Avadel Pharmaceuticals PLC is 1.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers.

Is Avadel Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether AVDL is over valued or under valued. Whether Avadel Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Avadel Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVDL.

What is Avadel Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AVDL's PE ratio (Price to Earnings) is -10.25 and Price to Sales (PS) ratio is 29.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVDL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Avadel Pharmaceuticals PLC's stock?

In the past 10 years, Avadel Pharmaceuticals PLC has provided 0.019 (multiply by 100 for percentage) rate of return.